187 related articles for article (PubMed ID: 22427209)
21. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
22. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.
Patt YZ; Murad W; Fekrazad MH; Baron AD; Bansal P; Boumber Y; Steinberg K; Lee SJ; Bedrick E; Du R; Lee FC
Cancer Med; 2017 Sep; 6(9):2042-2051. PubMed ID: 28801995
[TBL] [Abstract][Full Text] [Related]
23. Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.
Duffy AG; Ma C; Ulahannan SV; Rahma OE; Makarova-Rusher O; Cao L; Yu Y; Kleiner DE; Trepel J; Lee MJ; Tomita Y; Steinberg SM; Heller T; Turkbey B; Choyke PL; Peer CJ; Figg WD; Wood BJ; Greten TF
Clin Cancer Res; 2017 Aug; 23(16):4633-4641. PubMed ID: 28465443
[No Abstract] [Full Text] [Related]
24. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
Koeberle D; Dufour JF; Demeter G; Li Q; Ribi K; Samaras P; Saletti P; Roth AD; Horber D; Buehlmann M; Wagner AD; Montemurro M; Lakatos G; Feilchenfeldt J; Peck-Radosavljevic M; Rauch D; Tschanz B; Bodoky G;
Ann Oncol; 2016 May; 27(5):856-61. PubMed ID: 26884590
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.
He SL; Shen J; Sun XJ; Zhu XJ; Liu LM; Dong JC
World J Gastroenterol; 2013 Jul; 19(28):4552-8. PubMed ID: 23901232
[TBL] [Abstract][Full Text] [Related]
26. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.
Martin-Richard M; Gallego R; Pericay C; Garcia Foncillas J; Queralt B; Casado E; Barriuso J; Iranzo V; Juez I; Visa L; Saigi E; Barnadas A; Garcia-Albeniz X; Maurel J
Invest New Drugs; 2013 Dec; 31(6):1573-9. PubMed ID: 24077981
[TBL] [Abstract][Full Text] [Related]
27. Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Abou-Alfa GK; Blanc JF; Miles S; Ganten T; Trojan J; Cebon J; Liem AK; Lipton L; Gupta C; Wu B; Bass M; Hollywood E; Ma J; Bradley M; Litten J; Saltz LB
Oncologist; 2017 Jul; 22(7):780-e65. PubMed ID: 28592620
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
Makielski RJ; Lubner SJ; Mulkerin DL; Traynor AM; Groteluschen D; Eickhoff J; LoConte NK
Cancer Chemother Pharmacol; 2015 Aug; 76(2):317-23. PubMed ID: 26068189
[TBL] [Abstract][Full Text] [Related]
29. S-1 plus sorafenib for the treatment of advanced hepatocellular carcinoma.
Huang W; You L; Liu D; Yang S; Liu M; Wang H; Wang P; Baikere P; Gu P; Abulikemu A; Yuan S; Fan X
J BUON; 2016; 21(6):1388-1393. PubMed ID: 28039697
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
Chen D; Zhao P; Li SQ; Xiao WK; Yin XY; Peng BG; Liang LJ
Eur J Surg Oncol; 2013 Sep; 39(9):974-80. PubMed ID: 23845703
[TBL] [Abstract][Full Text] [Related]
31. Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.
Feng YM; Feng CW; Lu CL; Lee MY; Chen CY; Chen SC
Jpn J Clin Oncol; 2015 Apr; 45(4):336-42. PubMed ID: 25646358
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
Edeline J; Coulouarn C; Crouzet L; Pracht M; Lepareur N; Clément B; Garin E
J Vasc Interv Radiol; 2015 Dec; 26(12):1874-78.e2. PubMed ID: 26596183
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.
Asnacios A; Fartoux L; Romano O; Tesmoingt C; Louafi S S; Mansoubakht T; Artru P; Poynard T; Rosmorduc O; Hebbar M; Taieb J
Cancer; 2008 Jun; 112(12):2733-9. PubMed ID: 18412149
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.
Yau T; Wong H; Chan P; Yao TJ; Pang R; Cheung TT; Fan ST; Poon RT
Invest New Drugs; 2012 Dec; 30(6):2384-90. PubMed ID: 22402942
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies.
Patrikidou A; Sinapi I; Regnault H; Fayard F; Bouattour M; Fartoux L; Faivre S; Malka D; Ducreux M; Boige V
Invest New Drugs; 2014 Oct; 32(5):1028-35. PubMed ID: 24748335
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Tabernero J; Garcia-Carbonero R; Cassidy J; Sobrero A; Van Cutsem E; Köhne CH; Tejpar S; Gladkov O; Davidenko I; Salazar R; Vladimirova L; Cheporov S; Burdaeva O; Rivera F; Samuel L; Bulavina I; Potter V; Chang YL; Lokker NA; O'Dwyer PJ
Clin Cancer Res; 2013 May; 19(9):2541-50. PubMed ID: 23532888
[TBL] [Abstract][Full Text] [Related]
38. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
El Dika I; Capanu M; Chou JF; Harding JJ; Ly M; Hrabovsky AD; Do RKG; Shia J; Millang B; Ma J; O'Reilly EM; Abou-Alfa GK
Cancer Med; 2020 Oct; 9(20):7453-7459. PubMed ID: 32841541
[TBL] [Abstract][Full Text] [Related]
40. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
